Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis

Completed · Phase 3 · Has a placebo group

Conditions studied: Other Osteoporosis

In brief

Two year study to determine the safety and efficacy of weekly 35 mg Risedronate doses in men with osteoporosis followed by a two year follow-up study.

Key facts

Study ID

NCT00619957

Run by

Warner Chilcott

People needed

285

Starts

2002-06-01

Expected to finish

2007-05-01

Last updated by the study team

2011-10-28

Who can join

Age: 30 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Documented osteoporosis of the femoral neck and lumbar spine

You may not qualify if…

• BMI greater than or equal to 35

Where it is running

• Research Site — Palm Desert, California, United States
• Research Site — Lakewood, Colorado, United States
• Research Site — Stuart, Florida, United States
• Research Site — St Louis, Missouri, United States
• Research Facility — Cincinnati, Ohio, United States
• Research Site — Portland, Oregon, United States
• Research Site — Wyomissing, Pennsylvania, United States
• Research Facility — Concord, Australia
• Research Facility — Heidelburg, Australia
• Research Facility — Leuven, Belgium
• Research Site — Prague, Czechia
• Research Facility — Angers, France
• Research Site — Lyon, France
• Research Facility — Budapest, Hungary
• Research Site — Budapest, Hungary
• Research Site — Beirut, Lebanon
• Research Site — Rotterdam, Netherlands
• Research Site — Bialystok, Poland
• Research Site — Warsaw, Poland
• Research Site — Wroclaw, Poland
• Research Site — London, United Kingdom
• Research Site — Newcastle, United Kingdom
• Research Site — Sheffield, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.